Recruiting
International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020)
NCT07476729· Phase 3· Charite University, Berlin, Germany· Source
Recruiting
A Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or B
NCT07285460· Phase 3· Sanofi· Source
Active, not recruiting
A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids)
NCT07107945· Phase 3· Boehringer Ingelheim· Source
Recruiting
A Study of SGT-003 Gene Therapy in Ambulant Males With Duchenne Muscular Dystrophy (IMPACT DUCHENNE)
NCT07160634· Phase 3· Solid Biosciences Inc.· Source
Recruiting
A Study Evaluating the Effects of Filgotinib in Children and Teenagers With Ulcerative Colitis
NCT06865417· Phase 3· Alfasigma S.p.A.· Source
Contact: Patrick Bontems, MD
Recruiting
A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis
NCT07071519· Phase 3· AbbVie· Source
Recruiting
A study evaluating the effects of filgotinib in children and teenagers with ulcerative colitis
2024-511458-32-00· Phase 3· Alfasigma S.p.A.· Source
Recruiting
A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease
NCT06612268· Phase 3· Novo Nordisk A/S· Source
Recruiting
A Multi-Arm, Platform Trial For Relapsed Neuroblastoma
NCT07334301· Phase 1/2· University of Birmingham· Source
Recruiting
A Phase 2 Open-label (Core Phase Plus Extension Phase) With 2 Cohorts Study to Assess the Pharmacokinetics and Safety of Givinostat in DMD Patients Ages From at Least 2 Years to Less Than 6 Years Old
2024-511823-32-00· Phase 2· Italfarmaco S.p.A.· Source
Active, not recruiting
Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease
NCT06332534· Phase 3· AbbVie· Source
Recruiting
A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis
NCT06311682· Phase 3· LEO Pharma· Source
Recruiting
CHIP-AML22/Quizartinib: Quizartinib + Chemotherapy in Newly Diagnosed Pediatric FLT3-ITD+ and NPM1wt AML Patients
NCT06262438· Phase 2· Princess Maxima Center for Pediatric Oncology· Source
Active, not recruiting
A Study of Roxadustat to Treat Anemia in Children and Teenagers With Chronic Kidney Disease
NCT05970172· Phase 3· Astellas Pharma Global Development, Inc.· Source
Recruiting
A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease
NCT05995353· Phase 3· AbbVie· Source
Recruiting
A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Antiviral Activity of Maribavir for the Treatment of Cytomegalovirus (CMV) Infection in Children and Adolescents Who Have Received a Hematopoietic Stem Cell Transplant (HSCT) or a Solid Organ Transplant (SOT)
NCT05319353· Phase 3· Takeda· Source
Recruiting
CHIP-AML22 Master protocol: Protocol for the treatment of children and adolescents with Acute Myeloid Leukemia (AML)
2023-504999-25-00· Phase 3· Prinses Maxima Centrum voor Kinderoncologie B.V.· Source
Recruiting
Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia
NCT05327894· Phase 3· Princess Maxima Center for Pediatric Oncology· Source
Recruiting
A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria
NCT05457283· Phase 3· Bayer· Source
Recruiting
International Euro Ewing (iEuroEwing) trial for treatment optimisation in patients with Ewing sarcoma
2022-501180-40-00· Phase 3· GPOH gGmbH· Source
Recruiting
SIOP-HRMB: An international prospective trial on clinically high-risk medulloblastoma (HR-MB) in patients older than 3 years.
2024-510578-25-00· Phase 3· The University Of Birmingham· Source
Active, not recruiting
Evaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis
NCT04624230· Phase 3· Pfizer· Source
Recruiting
Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study
NCT04657822· Phase 4· Novartis Pharmaceuticals· Source
Recruiting
A Clinical Study to Assess Safety, Efficacy and Pharmacodynamic Profile of GNT0004 in Duchenne Muscular Dystrophy
NCT07856329· Phase 2/3· Genethon· Source
Enrolling by invitation
A Long-term Follow-up Study in Participants Who Received CTX001
NCT04208529· Phase 3· Vertex Pharmaceuticals Incorporated· Source
Recruiting
FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma
NCT04625907· Phase 1/2· University of Birmingham· Source
Recruiting
An international trial for children with atypical teratoid/rhabdoid tumours (ATRT)
2022-501456-28-00· Phase 3· GPOH gGmbH· Source
Recruiting
A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia
NCT04307576· Phase 3· Mats Heyman· Source
Recruiting
International study for children and adolescents with standard risk ALK-positive anaplastic large cell lymphoma (ALCL) estimating the efficacy of Vinblastine
2022-501454-11-00· Phase 3· GPOH gGmbH· Source
Recruiting
SIOP RANDOMET 2017
2023-508926-91-00· Phase 3· GPOH gGmbH· Source
Recruiting
High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)
NCT04221035· Phase 3· Gustave Roussy, Cancer Campus, Grand Paris· Source
Recruiting
A Study to Test GlaxoSmithKline's (GSK) Candidate Vaccine-GSK1437173A for Prevention of Shingles in Children With Kidney Transplant
NCT04006808· Phase 1/2· GlaxoSmithKline· Source
Recruiting
International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma
NCT04043494· Phase 3· University Hospital Muenster· Source
Active, not recruiting
A Study to Evaluate Efficacy and Safety of Perampanel Administered as an Adjunctive Therapy in Pediatric Participants With Childhood Epilepsy
NCT04015141· Phase 2· Eisai Inc.· Source
Recruiting
International Study for Treatment of High Risk Childhood Relapsed ALL 2010
NCT03590171· Phase 2· Charite University, Berlin, Germany· Source
Active, not recruiting
Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
NCT03007147· Phase 3· Children's Oncology Group· Source
Recruiting
SIOP Ependymoma II: An International Clinical Program for the diagnosis and treatment of children, adolescents and young adults with ependymoma
NCT02265770· Phase 2/3· Centre Leon Berard· Source
Active, not recruiting
International Society of Paediatric Oncology (SIOP) PNET 5 Medulloblastoma
NCT02066220· Phase 2/3· Universitätsklinikum Hamburg-Eppendorf· Source
Recruiting
Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma, ATRT and Rare CNS Tumors
NCT01356290· Phase 2· Medical University of Vienna· Source
Recruiting
Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia
NCT01949129· Phase 2/3· St. Anna Kinderkrebsforschung· Source
Recruiting
NOPHO-DBH AML 2012 Protocol: Research study for treatment of children and adolescents with acute myeloid leukemia 0-18 years
NCT01828489· Phase 3· Vaestra Goetalandsregionen· Source